Drug reference

Dulaglutide

GLP-1 Receptor Agonist · Antidiabetic

GLP-1 Receptor AgonistAntidiabetic

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

2 major

SEVERE in our sources

PREGNANCY

Manufacturer advises avoid—toxicity in animal studies

FDA category + note

Top interactions

BexaroteneSevereDatabaseDDInter
GatifloxacinSevereDatabaseDDInter

Mechanism

Dulaglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist. It augments glucose-dependent insulin secretion and slows gastric emptying.

Indications

Type 2 diabetes mellitus as monotherapy if metformin inappropriateType 2 diabetes mellitus in combination with insulin or other antidiabetic drugs (if existing treatment fails to achieve adequate glycaemic control)Treatment of diabetic patients (type 2 diabetes)Used with other antidiabetic agents

Dosing

Adult: Type 2 diabetes mellitus as monotherapy if metformin inappropriate: 0.75 mg once weekly by subcutaneous injection. Type 2 diabetes mellitus in combination with insulin or other antidiabetic drugs: 1.5 mg once weekly by subcutaneous injection. Dose of concomitant insulin or drugs that stimulate insulin secretion may need to be reduced.
Max dose: 1.5 mg once weekly

Pharmacokinetics

Half-life

Approximately 5 days

Contraindications

Severe gastro-intestinal disease
Pregnancy (manufacturer advises avoid due to toxicity in animal studies)

Side effects

Common

Appetite decreasedAtrioventricular blockBurpingConstipationDiarrhoeaFatigueGastrointestinal discomfortGastrointestinal disordersHypoglycaemiaNauseaSinus tachycardiaVomitingWeight loss

Serious

Anaphylactic reaction
Angioedema
Acute pancreatitis (discontinue)
Diabetic ketoacidosis (when concomitant insulin was rapidly reduced or discontinued)
Gallbladder disease (increased risk)
Pancreatitis (possible association)
Medullary carcinoma of the thyroid (contraindication)